Fujifilm Medical Systems USA has announced that as of October 1, it will incorporate in vitro diagnostics (IVD) into its portfolio by integrating Fujifilm Wako Diagnostics USA into the firm.
Fujifilm Wako Diagnostics has developed biomarkers that assess the risk of hepatocellular carcinoma in patients with chronic liver disease, as well as IVD reagents for disorders of lipid metabolism, lupus, rheumatoid arthritis, coronary heart disease, and diabetes, according to Fujifilm Medical Systems.
